Increasing the efficiency of islets of langerhans’ isolation from the donor's pancreas to obtain a biomedical cell product based on them

  • Ekaterina A. Nazarova Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Ekaterina G. Petrovskaya Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Anastasiya A. Gomon Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Evgeniya A. Primakova Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Alla A. Symanovich Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Nataliya I. Dedyulya Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Dmitrij A. Fedoruk Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Nikolaij M. Yakovets Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Svetlana I. Krivenko Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

Abstract

The progress of type I diabetes mellitus due to the destruction of the islets of Langerhans (IsL) and the subsequent progression of insulin deficiency are determined not only by genetic predisposition, but also by unfavorable environmental factors, the key ones of which are viral infections, air pollution, persistent organic pollutants, low physical activity and obesity. Clinical studies carried out over the past three decades have shown that the administration of isolated IsL or transplantation of the whole pancreas allows the restoration of β-cell function and the achievement of physiological release of endocrine hormones, to a greater extent than exogenous insulin in patients. The amount of freshly isolated IsL from one pancreas is insufficient for effective cell therapy. This study presents the results of modifying the conditions of the standard protocol for the islets of Langerhans’ isolating from the pancreas to increase the amount of biomedical cell product of this cells no less than 40%, in conditions of a limited donor’s material and to decrease the damaging proteolytic effect on the isolated cells. The object of the study was IsL isolated from the pancreas of donors with confirmed brain death.

Author Biographies

Ekaterina A. Nazarova, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

laboratory diagnostics doctor of the cell biotechnology laboratory

Ekaterina G. Petrovskaya, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

senior researcher of science department

Anastasiya A. Gomon, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

biologist of the HLA typing laboratory

Evgeniya A. Primakova, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

laboratory diagnostics doctor of the cell biotechnology laboratory

Alla A. Symanovich, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

PhD (biology); laboratory diagnostics doctor of the cell biotechnology laboratory

Dmitrij A. Fedoruk, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

surgeon of the department of transplantation

Nikolaij M. Yakovets, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

PhD (medicine); surgeon of the department of transplantation

Svetlana I. Krivenko, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

doctor of science (medicine), associate professor; deputy director for research

References

  1. International Diabet Federation [Internet]. [Cited 2019 August 04]. Available fom: https://www.idf.org/aboutdiabetes/type-1-diabetes.html.
  2. Oikarinen S, Hober D, Tauriainen S, et al. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes. 2014;63(2):655−662.
  3. Dotta F, Sebastiani G. Enteroviral Infections and Development of Type 1 Diabetes: The Brothers Karamazov Within the CVBs. Diabetes. 2014;63(2):384−386.
  4. Bowe B, Xie Y, Li T, et al. The 2016 global and national burden of diabetes mellitus attributable to PM 2·5 air pollution. Lancet Planet Health. 2018;2(7):301−312.
  5. O’Donovan G, Cadena-Gaitán C. Air pollution and diabetes: it’s time to get active! Lancet Planet Health. 2018;2(7):287−288.
  6. Зайчик АШ, Чурилов ЛП. Основы патохимии. Санкт-Петербург: ЭЛБИ-СПБ; 2001. 688 с.
  7. Пигаревский ПВ, Мальцева СВ, Селивестрова ВГ. Иммунная система, атеросклероз и персистирующая инфекция. Вестник РАМН. 2005;2:17−22.
  8. Романова ЕА, Чапова ОИ. Сахарный диабет. Москва: Эксмо; 2004. 448 с.
  9. Лавин Н. Эндокринология. Москва: Практика; 1999. 346 с.
  10. Gregg EW, LiY, Wang J, et al. Changes in diabetes-related complications in the United States, 1990−2010. New England Journal of Medicine. 2014;370:1514−1523.
  11. Mannucci E, Monami M, Dicembrini I, et al. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. Journal of Endocrinological Investigation. 2014;37:477−495.
  12. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine. 2000;343:230−238.
  13. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060–2069.
  14. Collaborative Islet Transplant Registry Annual Reports. [Internet]. [Cited November 12]. Available from: https://web.emmes.com/study/isl/reports/reports.htm.
  15. Shapiro AM, Ricordi C, et al. International Trial of the Edmonton Protocol for Islet Transplantation. New England Journal of Medicine. 2006;35:1318−1330.
  16. Gerber PA, Pavlicek V, Demartines N, et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia. 2008;51:110−119.
  17. Cure P, Pileggi A, Froud T, et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation. 2008;85:801−812.
  18. Leitao CB, Cure P, Messinger S, et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation. 2009;87:681−688.
  19. Thompson DM, Meloche M, Ao Z, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011;91:373−378.
  20. Fiorina P, Venturini M, Folli F, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care. 2005;28:1303−1310.
  21. Senior PA, Zeman M, Paty BW, et al. Changes in renal function after clinical islet transplantation: four-year observational study. American Journal Transplantation. 2007;7:91−98.
  22. Gillard P, Rustandi M, Efendi A, et al. Early Alteration of Kidney Function in Nonuremic Type 1 Diabetic Islet Transplant Recipients Under Tacrolimus-Mycophenolate Therapy. Transplantation. 2014;98(4):451−457.
  23. Lee TC, Barshes NR, O’Mahony CA, et al. The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy. Transplantation Proceedings. 2005;37:2263−2265.
  24. Vantyghem MC, Quintin D, Caiazzo R, et al. Improvement of electrophysiological neuropathy after islet transplantation for type 1 diabetes: a 5-year prospective study. Diabetes Care. 2014;37:141−142.
  25. D’Addio F, Maffi P, Vezzulli P, et al. Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes. Diabetes Care. 2014;37:267−276.
  26. Danielson KK, Hatipoglu B, Kinzer K, et al. Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 diabetes. Diabetes Care. 2013;36:450−456.
  27. Fiorina P., Folli F., Bertuzzi F., et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care. 2003;26:1129−1136.
  28. Warnock GL, Thompson DM, Meloche RM, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008;86:1762−1766.
  29. Mineo D, Pileggi A, Alejandro R, et al.. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care. 2009;32:1563−1569.
  30. Pellegrini S, Cantarelli E, Sordi V, et al. The state of the art of islet transplantation and cell therapy in type 1 diabetes. Acta Diabetologica. 2016;53(5):683−691.
  31. Linetsky E. Human pancreatic islet isolation (SOP ICPF-001, attachment I) Origin version 06-95, revision 12, p. 1−43.
  32. Назарова ЕА, Кривенко СИ, Федорук АМ, Коритко АА, Гомон АА, Петровская ЕГ. Способ получения островковых комплексов поджелудочной железы человека. Патент BY 20789. Опубликовано 09.11.2016 г.
  33. Linetsky E. Islet isolation media preparation form (SOP ICPF-002, attachment V) Origin version 06-95, revision 12, p. 1−2.
  34. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37:413−420.
  35. Lake SP, Bassett PD, Larkins A, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes. 1989;38(1): 143−145.
  36. Barbaro B, et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation. 2007;84:1200−1203.
Published
2021-01-15
Keywords: islets of Langerhans, biomedical cell product, type I diabetes mellitus
How to Cite
Nazarova, E. A., Petrovskaya, E. G., Gomon, A. A., Primakova, E. A., Symanovich, A. A., Dedyulya, N. I., Fedoruk, D. A., Yakovets, N. M., & Krivenko, S. I. (2021). Increasing the efficiency of islets of langerhans’ isolation from the donor’s pancreas to obtain a biomedical cell product based on them. Journal of the Belarusian State University. Ecology, 4, 70-78. Retrieved from https://journals.bsu.by/index.php/ecology/article/view/3646
Issue
No 4 (2020): Journal of the Belarusian State University. Ecology
Section
Medical Ecology